AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a plan to save $1.5 billion (1.34 billion euros) a year to reinvest in new drug development.
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a plan to save $1.5 billion (1.34 billion euros) a year to reinvest in new drug development.
🇬🇧 UK · Map
More on Radar
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in